8-K: Aprea Therapeutics Secures $5.6M, Reports Positive Clinical Data

Aprea Therapeutics announced a $5.6 million private placement and early clinical proof-of-concept for its WEE1 inhibitor, APR-1051, including an unconfirmed partial response in an endometrial cancer patient.

Summary

• Aprea Therapeutics entered into a securities purchase agreement with accredited investors for a private placement, expected to generate approximately $5.6 million in gross proceeds.
• The offering includes 6,288,857 shares of common stock (or pre-funded warrants) and common stock purchase warrants for up to 6,288,857 shares.
• The combined effective offering price is $0.89 per share/pre-funded warrant and accompanying common warrant, with a common warrant exercise price of $0.765 per share.
• The company announced early clinical proof-of-concept for its WEE1 inhibitor, APR-1051, in the ongoing Phase 1 ACESOT-1051 dose-escalation study.
• An unconfirmed partial response (uPR) was observed in a patient with PPP2R1A-mutated uterine serous carcinoma (endometrial cancer) at the 150 mg dose, showing a 50% tumor reduction and over 90% decrease in CA-125 levels.
• Other patients in earlier cohorts achieved stable disease with tumor reductions, including a 5% reduction in HPV-positive HNSCC at 70 mg and a 15% reduction in FBXW7-mutated colon cancer at 100 mg.
• The private placement proceeds will be used for general corporate purposes and research and development expenses, specifically to backfill patients in the ACESOT-1051 study to accelerate dose optimization.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, driven by a successful capital raise that extends the cash runway and encouraging early clinical data for APR-1051, despite the inherent risks of clinical-stage biotech and dilution.

Positives

• Secured approximately $5.6 million in gross proceeds from a private placement, strengthening the company's financial position.
• Observed an unconfirmed partial response (uPR) with APR-1051 in a heavily pretreated endometrial cancer patient, demonstrating early clinical activity.
• Multiple patients achieved stable disease with tumor reductions in the Phase 1 ACESOT-1051 study, suggesting broader therapeutic potential.
• A potential dose-response trend and favorable safety profile for APR-1051 were observed in the ongoing dose-escalation study.
• The company's WEE1 inhibitor, APR-1051, shows high selectivity with minimal inhibition of PLK1, PLK2, or PLK3, potentially leading to a better safety profile compared to competitors.
• The amendment to the December 2025 Securities Purchase Agreement lifts previous restrictions on issuing new securities earlier, facilitating the current capital raise.

Negatives

• The private placement will result in dilution for existing shareholders due to the issuance of new shares and warrants.
• Monotherapy enrollment for the ATR inhibitor ATRN-119 has been paused, with the company now considering combination approaches, indicating a shift in strategy for this program.

Risks

• The success, timing, and cost of ongoing and anticipated clinical trials for product candidates, including the timing of initiation, pace of enrollment, and completion of trials.
• The ability to fully fund disclosed clinical trials, which assumes no material changes to currently projected expenses.
• Futility analyses, presentations at conferences, and data reported in abstracts, and receipt of interim or preliminary results (including preclinical data), which are not necessarily indicative of final clinical trial results.
• The company's understanding of product candidates' mechanisms of action and interpretation of preclinical and early clinical results, and the ability to predict clinical outcomes based on such results.
• Risks related to the company's ability to continue as a going concern.
• Market and other conditions, as well as other factors described under 'Risk Factors' in SEC filings.

Future Outlook

The company expects the private placement to extend its cash runway into Q1 2027, enabling it to fund ongoing research and development. Management anticipates accelerating dose optimization for APR-1051 by proactively backfilling patients, aiming to define the optimal dose and patient population to drive the program toward clinical and value-creating inflection points. Additional updates for APR-1051 safety/efficacy data are expected in Q1 2026, with dose escalation completion targeted for Q3 2026. For ATRN-119, the company is pausing monotherapy enrollment to consider combination approaches that could expand its therapeutic potential.

Management Comments

• "We believe this financing will enable us to proactively backfill patients at key dose levels in our ongoing ACESOT-1 dose-escalation study evaluating APR-1051, our WEE1 kinase inhibitor, and this may increase the likelihood of successful dose optimization." Oren Gilad, CEO of Aprea Therapeutics.
• "By adding more patients to our safety and early efficacy dataset, we expect to accelerate our ability to define the optimal dose and patient population, which we believe will drive the program toward clinical and value-creating inflection points." Oren Gilad, CEO of Aprea Therapeutics.
• "These early single-agent data demonstrate that APR-1051 has clinical activity as a single agent... The observation of a partial response on the first scan, together with a decrease in tumor marker at this dose level, supports continued clinical evaluation of APR-1051." Anthony Tolcher, MD, FRCPC, Principal Investigator at Next Oncology.
• "These preliminary results provide early proof-of-concept for single-agent activity of APR-1051 and support our strategy of targeting cancers with specific genomic alterations, including HPV-positive disease and PPP2R1A, FBXW7, CCNE1, TP53 and KRAS mutations." Oren Gilad, CEO of Aprea Therapeutics.
• "The potential dose-response trend and favorable safety profile observed in the ongoing dose-escalation study reinforce our confidence in the potential of APR-1051 as a differentiated WEE1 inhibitor for patients with advanced solid tumors. We look forward to providing additional updates in the first half of 2026 and completing dose escalation later in the year." Oren Gilad, CEO of Aprea Therapeutics.

Industry Context

StockSavvy.ai notes that Aprea Therapeutics operates in the highly competitive and innovative precision oncology space, focusing on DNA Damage Response (DDR) inhibition through synthetic lethality. This approach, which exploits cancer-specific genetic weaknesses while sparing healthy cells, is a clinically validated and growing area in cancer treatment. The market is driven by a shift towards targeted therapies and combinations, aiming for improved efficacy and better safety profiles. Aprea's focus on WEE1 and ATR inhibitors positions it within a key segment of DDR research, where differentiation in selectivity and safety can be a significant competitive advantage.

Comparison to Industry Standards

• APR-1051, Aprea's WEE1 inhibitor, is highlighted as 'potentially best-in-class' due to its high selectivity and minimal inhibition of PLK1, PLK2, or PLK3. This contrasts with competitors like Zentalis's Azenosertib (ZN-c3) and AstraZeneca's Adavosertib (AZD-1775), which have shown significant off-target PLK inhibition.
• Specifically, APR-1051's PLK1 inhibition IC50 is >150-fold higher than ZN-c3 (15,900 nM vs. 92.1 nM), PLK2 inhibition IC50 is >50-fold higher (1,800 nM vs. 32.0 nM), and PLK3 inhibition IC50 is >600-fold higher (31,600 nM vs. 52.2 nM).
• This reduced off-target activity is presented as a potential advantage, as PLK1 suppression has been associated with adverse effects like sepsis-induced loss of intestinal barrier function in studies, suggesting APR-1051 may offer an improved safety profile compared to WEE1 inhibitors with higher PLK inhibition.
• The clinical activity of WEE1 inhibitors, such as Adavosertib, has been demonstrated in Phase 2 studies for recurrent uterine serous carcinoma (29.4% ORR) and refractory solid tumors with CCNE1 amplification (27% ORR), providing a benchmark for APR-1051's early clinical proof-of-concept.

Related Party Transactions

• Certain insiders of the company participated in the private placement, purchasing shares of common stock or pre-funded warrants and accompanying common warrants.

Stakeholder Impact

• **Shareholders**: Experience dilution from the issuance of new shares and warrants, but benefit from extended cash runway and potential value creation from positive clinical trial results.
• **Investors (new)**: Gain exposure to Aprea Therapeutics at a specified price, with warrants offering additional upside potential.
• **Patients**: Potential for new, targeted treatment options for advanced solid tumors, particularly those with specific genomic alterations, based on promising early clinical data.
• **Employees**: Continued employment and R&D efforts supported by the capital raise, potentially leading to further program advancements.
• **Creditors**: Improved financial stability and extended cash runway may reduce short-term credit risk.

Next Steps

• Closing of the private placement is expected on January 30, 2026.
• The company will file a registration statement for the resale of the securities purchased in the private placement by the 60th day after the closing date.
• Continue enrollment in the 220 mg dose level cohort of the ACESOT-1051 study for APR-1051.
• Increase enrollment of HPV-positive patients in the ongoing ACESOT-1051 trial.
• Provide additional updates on APR-1051 safety/efficacy data in Q1 2026.
• Complete dose escalation for APR-1051 later in 2026, specifically targeting Q3 2026.
• Evaluate optimal strategic partnerships for the company's programs.
• Consider combination approaches for ATRN-119 development after pausing monotherapy enrollment.

Key Dates

Recommendation

The capital raise provides necessary funding and extends the company's cash runway, which is a positive for stability. The early clinical data for APR-1051, including an unconfirmed partial response and stable disease in multiple patients, is promising and suggests therapeutic potential. However, these are still early-stage Phase 1 results, and the long-term success of the drug candidates remains uncertain. The dilution from the capital raise is a factor, and the shift in strategy for ATRN-119 indicates ongoing development challenges. A 'hold' recommendation reflects the balance between these encouraging early signs and the significant risks inherent in clinical-stage biopharmaceutical development.

Keywords

Aprea Therapeutics, APRE, Private Placement, WEE1 Inhibitor, APR-1051, ATR Inhibitor, ATRN-119, Clinical Trial, Phase 1, Oncology, Cancer, Endometrial Cancer, Solid Tumors, PPP2R1A, FBXW7, HPV-positive, Capital Raise, Securities Purchase Agreement, Warrants, Nasdaq, Biopharmaceutical, Synthetic Lethality, DNA Damage Response